The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

Bisphosphonates are effective in the management of bone disease in patients with multiple myeloma and recent reports have suggested that they may also have an anti-tumour activity. In support of this, we have previously demonstrated that bisphosphonates can induce myeloma cell apoptosis in vitro; ho...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Shipman, C, Vanderkerken, K, Rogers, M, Lippitt, J, Asosingh, K, Hughes, D, Van Camp, B, Russell, R, Croucher, P
التنسيق:	Journal article
اللغة:	English
منشور في:	2000

مواد مشابهة

Bisphosphonates--mechanisms of action in multiple myeloma.
حسب: Shipman, C, وآخرون
منشور في: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
حسب: Croucher, P, وآخرون
منشور في: (2003)

Bisphosphonates and in vivo models of multiple myeloma - Reply
حسب: Shipman, C, وآخرون
منشور في: (2001)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
حسب: Vanderkerken, K, وآخرون
منشور في: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
حسب: Croucher, P, وآخرون
منشور في: (2001)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
حسب: Shipman, C, وآخرون
منشور في: (1997)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
حسب: Shipman, C, وآخرون
منشور في: (1998)

Anti-tumour activity of bisphosphonates in human myeloma cells.
حسب: Shipman, C, وآخرون
منشور في: (1998)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
حسب: Croucher, P, وآخرون
منشور في: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
حسب: Croucher, P, وآخرون
منشور في: (2001)

Osteoprotegerin and the development of myeloma bone disease
حسب: Croucher, P, وآخرون
منشور في: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
حسب: Croucher, P, وآخرون
منشور في: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
حسب: Croucher, P, وآخرون
منشور في: (2001)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
حسب: Croucher, P, وآخرون
منشور في: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
حسب: Shipman, C, وآخرون
منشور في: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
حسب: Shipman, C, وآخرون
منشور في: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
حسب: Mueller, G, وآخرون
منشور في: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
حسب: Mueller, G, وآخرون
منشور في: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
حسب: Shipman, C, وآخرون
منشور في: (2002)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
حسب: Gordon, S, وآخرون
منشور في: (1999)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
حسب: Edwards, C, وآخرون
منشور في: (2007)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
حسب: De Leenheer, E, وآخرون
منشور في: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
حسب: Shipman, C, وآخرون
منشور في: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
حسب: De Leenheer, E, وآخرون
منشور في: (2002)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
حسب: Locklin, R, وآخرون
منشور في: (2005)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
حسب: Croucher, P, وآخرون
منشور في: (2003)

The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells
حسب: Roelofs, A, وآخرون
منشور في: (2006)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
حسب: Richard Derman, وآخرون
منشور في: (2009-09-01)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
حسب: Locklin, R, وآخرون
منشور في: (2007)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
حسب: Liesbeth Bieghs, وآخرون
منشور في: (2010-01-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
حسب: Shipman, C, وآخرون
منشور في: (2002)

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia
حسب: Nutrisia Aquariushinta Sayuti, وآخرون
منشور في: (2020-09-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
حسب: Shipman, C, وآخرون
منشور في: (2003)

Administration of bisphosphonate (ibandronate) impedes molar tooth movement in rabbits: A radiographic assessment
حسب: V Venkataramana, وآخرون
منشور في: (2014-01-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
حسب: Clive Henry Buckle, وآخرون
منشور في: (2012-01-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
حسب: Jagdev, S, وآخرون
منشور في: (2001)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
حسب: Roelofs, A, وآخرون
منشور في: (2004)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
حسب: Locklin, R, وآخرون
منشور في: (2007)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
حسب: Maria Nieves Lopez Muñoz, وآخرون
منشور في: (2023-08-01)

The pharmacology of bisphosphonates and new insights into their mechanisms of action.
حسب: Russell, R, وآخرون
منشور في: (1999)